ArticleJournal of orthopaedic surgery and research2026
Decoding resistance: a comprehensive study on pathogens and antibiotic efficacy in periprosthetic joint infections.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeriprosthetic joint infection (PJI) continues to be a severe complication following total joint arthroplasty (TJA). Identifying the causative pathogens and their antibiotic resistance profiles is essential for the effective eradication. MATERIALS AND
methodsIn this retrospective study, 825 antibiograms and demographic data of patients with confirmed PJIs from 2005 to 2021 were evaluated. The resistance profile evaluation focused on the antibiotics ampicillin/sulbactam, clindamycin, gentamicin, vancomycin, ciprofloxacin and rifampicin.
resultsMethicillin-sensitive staphylococcus aureus (MSSA) was the most prevalent pathogen (20.8%) followed by methicillin-resistant staphylococcus epidermidis (MRSE, 16.1%) and methicillin-sensitive staphylococcus epidermidis (MSSE, 10.8%). Polymicrobial (PM) PJI (15.9%) was also high with MSSA (21.2%) as the most frequent pathogen followed by gram-negative (GN) pathogens (20.2%) and MRSE (18.3%). The overall resistance rate against ampicillin/sulbactam and clindamycin was 42.3% and 40%, respectively. Vancomycin showed low resistance rates of nearly 1% with higher rates in enterococci (4%). MSSA and MRSA exhibit high sensitivity rates against gentamicin (97.4% and 89.5%). Gentamicin resistance was high in staphylococcus epidermidis (43%) and particularly in MRSE (64.6%). Ciprofloxacin resistance was especially high among MRSA (81.3%) and MRSE (84.0%) isolates, whereas sensitivity was most common in GN (78.5%) and MSSE (85.0%) groups. This study reveals high rates of MRSE, SE and GN pathogens causing PJI. GN and MRSE rates were also increased in PM PJI. The high overall resistance rates against ampicillin/sulbactam raise doubts as first line empiric oral antibiotic in PJI. The nearly 20% ciprofloxacin resistant GN pathogens should be alarming due to limited choice of biofilm-penetrating antibiotics in GN PJI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.